Anika Therapeutics Inc. (ANIK)
Anika Therapeutics Statistics
Share Statistics
Anika Therapeutics has 14.18M shares outstanding. The number of shares has increased by 0.03% in one year.
| Shares Outstanding | 14.18M |
| Shares Change (YoY) | 0.03% |
| Shares Change (QoQ) | -1.02% |
| Owned by Institutions (%) | 84.84% |
| Shares Floating | 13.63M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 402.31K, so 2.75% of the outstanding shares have been sold short.
| Short Interest | 402.31K |
| Short % of Shares Out | 2.75% |
| Short % of Float | 2.85% |
| Short Ratio (days to cover) | 5.2 |
Valuation Ratios
The PE ratio is -4.3 and the forward PE ratio is 35.62. Anika Therapeutics's PEG ratio is 0.13.
| PE Ratio | -4.3 |
| Forward PE | 35.62 |
| PS Ratio | 2.02 |
| Forward PS | 0.9 |
| PB Ratio | 1.57 |
| P/FCF Ratio | -103.95 |
| PEG Ratio | 0.13 |
Enterprise Valuation
Anika Therapeutics Inc. has an Enterprise Value (EV) of 288.27M.
| EV / Earnings | -5.11 |
| EV / Sales | 2.4 |
| EV / EBITDA | -56.51 |
| EV / EBIT | -56.51 |
| EV / FCF | -123.67 |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.17.
| Current Ratio | 4.88 |
| Quick Ratio | 3.85 |
| Debt / Equity | 0.17 |
| Total Debt / Capitalization | 14.41 |
| Cash Flow / Debt | 0.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.37% and return on capital (ROIC) is -9.06%.
| Return on Equity (ROE) | -0.37% |
| Return on Assets (ROA) | -0.28% |
| Return on Capital (ROIC) | -9.06% |
| Revenue Per Employee | $416,343.75 |
| Profits Per Employee | $-195,781.25 |
| Employee Count | 288 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 1.84 |
Taxes
| Income Tax | 6.06M |
| Effective Tax Rate | -2.19 |
Stock Price Statistics
The stock price has increased by -40.31% in the last 52 weeks. The beta is 0.95, so Anika Therapeutics's price volatility has been higher than the market average.
| Beta | 0.95 |
| 52-Week Price Change | -40.31% |
| 50-Day Moving Average | 16.8 |
| 200-Day Moving Average | 21.21 |
| Relative Strength Index (RSI) | 35.42 |
| Average Volume (20 Days) | 72K |
Income Statement
In the last 12 months, Anika Therapeutics had revenue of 119.91M and earned -56.38M in profits. Earnings per share was -3.83.
| Revenue | 119.91M |
| Gross Profit | 76M |
| Operating Income | -5.1M |
| Net Income | -56.38M |
| EBITDA | -5.1M |
| EBIT | -5.1M |
| Earnings Per Share (EPS) | -3.83 |
Balance Sheet
The company has 55.63M in cash and 25.93M in debt, giving a net cash position of 29.7M.
| Cash & Cash Equivalents | 55.63M |
| Total Debt | 25.93M |
| Net Cash | 29.7M |
| Retained Earnings | 71.67M |
| Total Assets | 202.74M |
| Working Capital | 90.35M |
Cash Flow
In the last 12 months, operating cash flow was 5.4M and capital expenditures -7.73M, giving a free cash flow of -2.33M.
| Operating Cash Flow | 5.4M |
| Capital Expenditures | -7.73M |
| Free Cash Flow | -2.33M |
| FCF Per Share | -0.16 |
Margins
Gross margin is 63.38%, with operating and profit margins of -4.25% and -47.02%.
| Gross Margin | 63.38% |
| Operating Margin | -4.25% |
| Pretax Margin | -2.31% |
| Profit Margin | -47.02% |
| EBITDA Margin | -4.25% |
| EBIT Margin | -4.25% |
| FCF Margin | -1.94% |
Dividends & Yields
ANIK does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -25.26% |
| FCF Yield | -1.08% |
Analyst Forecast
The average price target for ANIK is $22, which is 45.1% higher than the current price. The consensus rating is "Hold".
| Price Target | $22 |
| Price Target Difference | 45.1% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | 4.21 |
| Piotroski F-Score | 2 |